Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115543909> ?p ?o ?g. }
- W2115543909 endingPage "6729" @default.
- W2115543909 startingPage "6719" @default.
- W2115543909 abstract "Purpose To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin. Patients and Methods Forty-six pretreated patients with CD22+ non-Hodgkin's lymphoma (NHL; n = 4), chronic lymphocytic leukemia (CLL; n = 11), and hairy cell leukemia (HCL; n = 31) received 265 cycles at 3 to 50 μg/Kg every other day × 3 doses. Results BL22 was active in HCL, with 19 complete remissions (CRs; 61%) and six partial responses (PRs; 19%) in 31 patients. Of 19 CRs, 11 were achieved after one cycle and eight after two to 14 cycles. All 25 responders benefited clinically with one cycle. The CR rate was 86% in patients enrolled at ≥ 40 μg/Kg every other day × 3, and 41% at lower doses (P = .011). The median duration for CR was 36 months (range, 5 to 66 months), and eight patients remain in CR at 45 months (range, 29 to 66 months). Lower but significant activity occurred in CLL. Neutralizing antibodies occurred in 11 (24%) of 46 patients (all HCL). A reversible hemolytic uremic syndrome requiring plasmapheresis was observed in one patient with NHL during cycle 1 and in four patients with HCL during cycle 2 or 3. The maximum-tolerated dose (MTD) evaluated at cycle 1 was 40 μg/Kg IV. QOD × 3. The most common toxicities at 30 to 50 μg/Kg every other day × 3 included hypoalbuminemia, transaminase elevations, fatigue, and edema. Conclusion BL22 was well tolerated and highly effective in HCL, even after one cycle. Phase II testing is underway to define the efficacy with one cycle and to study safety when additional cycles are needed for optimal response." @default.
- W2115543909 created "2016-06-24" @default.
- W2115543909 creator A5025737516 @default.
- W2115543909 creator A5041784203 @default.
- W2115543909 creator A5049385918 @default.
- W2115543909 creator A5056573254 @default.
- W2115543909 creator A5059713612 @default.
- W2115543909 creator A5065696086 @default.
- W2115543909 creator A5082882030 @default.
- W2115543909 date "2005-09-20" @default.
- W2115543909 modified "2023-10-16" @default.
- W2115543909 title "Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies" @default.
- W2115543909 cites W125160567 @default.
- W2115543909 cites W129142841 @default.
- W2115543909 cites W1444134552 @default.
- W2115543909 cites W1518280877 @default.
- W2115543909 cites W159715420 @default.
- W2115543909 cites W1624744767 @default.
- W2115543909 cites W1912693401 @default.
- W2115543909 cites W1928244181 @default.
- W2115543909 cites W1952486334 @default.
- W2115543909 cites W1981521569 @default.
- W2115543909 cites W1992291725 @default.
- W2115543909 cites W2023435505 @default.
- W2115543909 cites W2025498393 @default.
- W2115543909 cites W2027751338 @default.
- W2115543909 cites W2028509782 @default.
- W2115543909 cites W2029304955 @default.
- W2115543909 cites W2041047147 @default.
- W2115543909 cites W2052275340 @default.
- W2115543909 cites W2053584187 @default.
- W2115543909 cites W2056546263 @default.
- W2115543909 cites W2057258583 @default.
- W2115543909 cites W2062085883 @default.
- W2115543909 cites W2062086371 @default.
- W2115543909 cites W2062093709 @default.
- W2115543909 cites W2072767834 @default.
- W2115543909 cites W2078641935 @default.
- W2115543909 cites W2101239339 @default.
- W2115543909 cites W2109896022 @default.
- W2115543909 cites W2116062997 @default.
- W2115543909 cites W2142998407 @default.
- W2115543909 cites W2150694237 @default.
- W2115543909 cites W2154899335 @default.
- W2115543909 cites W2255051461 @default.
- W2115543909 cites W2280026738 @default.
- W2115543909 cites W2335889607 @default.
- W2115543909 cites W238066860 @default.
- W2115543909 cites W2399875821 @default.
- W2115543909 cites W3022233986 @default.
- W2115543909 cites W4236953080 @default.
- W2115543909 cites W4238378618 @default.
- W2115543909 cites W4256483469 @default.
- W2115543909 cites W61507981 @default.
- W2115543909 cites W6178139 @default.
- W2115543909 cites W7247331 @default.
- W2115543909 doi "https://doi.org/10.1200/jco.2005.11.437" @default.
- W2115543909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16061911" @default.
- W2115543909 hasPublicationYear "2005" @default.
- W2115543909 type Work @default.
- W2115543909 sameAs 2115543909 @default.
- W2115543909 citedByCount "254" @default.
- W2115543909 countsByYear W21155439092012 @default.
- W2115543909 countsByYear W21155439092013 @default.
- W2115543909 countsByYear W21155439092014 @default.
- W2115543909 countsByYear W21155439092015 @default.
- W2115543909 countsByYear W21155439092016 @default.
- W2115543909 countsByYear W21155439092017 @default.
- W2115543909 countsByYear W21155439092018 @default.
- W2115543909 countsByYear W21155439092019 @default.
- W2115543909 countsByYear W21155439092020 @default.
- W2115543909 countsByYear W21155439092021 @default.
- W2115543909 countsByYear W21155439092022 @default.
- W2115543909 countsByYear W21155439092023 @default.
- W2115543909 crossrefType "journal-article" @default.
- W2115543909 hasAuthorship W2115543909A5025737516 @default.
- W2115543909 hasAuthorship W2115543909A5041784203 @default.
- W2115543909 hasAuthorship W2115543909A5049385918 @default.
- W2115543909 hasAuthorship W2115543909A5056573254 @default.
- W2115543909 hasAuthorship W2115543909A5059713612 @default.
- W2115543909 hasAuthorship W2115543909A5065696086 @default.
- W2115543909 hasAuthorship W2115543909A5082882030 @default.
- W2115543909 hasBestOaLocation W21155439091 @default.
- W2115543909 hasConcept C104317684 @default.
- W2115543909 hasConcept C115085202 @default.
- W2115543909 hasConcept C126322002 @default.
- W2115543909 hasConcept C141071460 @default.
- W2115543909 hasConcept C159654299 @default.
- W2115543909 hasConcept C181199279 @default.
- W2115543909 hasConcept C182179738 @default.
- W2115543909 hasConcept C185592680 @default.
- W2115543909 hasConcept C203014093 @default.
- W2115543909 hasConcept C2776009029 @default.
- W2115543909 hasConcept C2776877979 @default.
- W2115543909 hasConcept C2777938653 @default.
- W2115543909 hasConcept C2778461978 @default.
- W2115543909 hasConcept C2779338263 @default.
- W2115543909 hasConcept C40767141 @default.